Paradigm Medical Industries (OTCMKTS:PDMI) vs. IQVIA (NYSE:IQV) Head-To-Head Comparison

Paradigm Medical Industries (OTCMKTS:PDMI) and IQVIA (NYSE:IQV) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.

Earnings and Valuation

This table compares Paradigm Medical Industries and IQVIA”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paradigm Medical Industries	N/A	N/A	N/A	N/A	N/A
IQVIA	$16.31 billion	1.83	$1.36 billion	$8.07	22.12

IQVIA has higher revenue and earnings than Paradigm Medical Industries.

Volatility and Risk

Paradigm Medical Industries has a beta of -1.65, indicating that its share price is 265% less volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Paradigm Medical Industries and IQVIA, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Paradigm Medical Industries	0	0	0	0	0.00
IQVIA	0	2	13	2	3.00

IQVIA has a consensus price target of $225.69, indicating a potential upside of 26.45%. Given IQVIA’s stronger consensus rating and higher possible upside, analysts plainly believe IQVIA is more favorable than Paradigm Medical Industries.

Insider & Institutional Ownership

89.6% of IQVIA shares are held by institutional investors. 11.1% of Paradigm Medical Industries shares are held by insiders. Comparatively, 1.7% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Paradigm Medical Industries and IQVIA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Paradigm Medical Industries	N/A	N/A	N/A
IQVIA	8.33%	30.50%	6.53%

Summary

IQVIA beats Paradigm Medical Industries on 10 of the 11 factors compared between the two stocks.

About Paradigm Medical Industries

Paradigm Medical Industries, Inc. develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters. It also provides corneal topographers, such as PARAVUE 300 for diagnostic and contact lens applications, as well as SURVEYOR 500 for cornea and anterior segment; PARAMAX, which analyzes the functionality of ganglion cells and identifies glaucoma suspects; P60 and P60 ACI ultrasound biomicroscopes; and PARACAM 1000, a non-contact endothelial microscope, as well as software and accessories. The company was founded in 1989 and is based in Salt Lake City, Utah.

About IQVIA

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.